PHOENIX, Dec. 12, 2017 /PRNewswire-USNewswire/ -- Paradigm is pleased to announce an upgrade to our offering. All Paradigm Cancer Diagnostic (PCDx) tests ordered for patients with lung cancer now also include 17 fusions, as well as EGFR and MET skipping events. The fusions include: ALK, AXL, BRAF, CCND1, FGFR1, FGFR2, FGFR3, MET, NGR1, NTRK1, NTRK2, NTRK3, PPARG, RAF1, RET, ROS1 and THADA.
The fusion panel may also be ordered as an add-on for any PCDx patients and will be delivered within in our standard 5 day turnaround time with our customary high level of accuracy. We use anchored PCR technology on RNA to detect known and novel fusions with high sensitivity using our current tissue requirement of 4% or greater tumor content in a single core needle biopsy or fine needle aspirate.
"The new fusion panel addition detects the fusion partners and the break points, which aren't captured by FISH," said Dr. Scott Morris, Paradigm's Chief Scientific Officer. "For instance, in EML4-ALK, we distinguish between variant 1 and other variants which can also be important to help guide treatment."
PCDx is a clinical-grade comprehensive sequencing test that covers DNA, RNA, fusions and immunohistochemistry and interrogates the most actionable targets with a 5,000x average depth of coverage and delivers a report in five business days using the latest evidence with associations including associations to up to 87 different FDA approved therapies and 19 combinations. Because of the exceptional accuracy of PCDx, formalin fixed paraffin embedded (FFPE) specimens can be fully processed with as little as four percent tumor present, including those from fine needle aspirates.
In addition to being certified under the Clinical Laboratory Improvement Amendments (CLIA) Paradigm has also been awarded accreditation by the College of American Pathologists (CAP).
PCDx may be ordered by completing a requisition on the website www.paradigmdx.com and is covered by most insurance plans including Medicare.
Paradigm Diagnostics offers accurate, comprehensive and clinically actionable cancer genomic profiling and therapeutic information, in an average of 5 business days to better support patient care. The Paradigm Cancer Diagnostic (PCDx) comprehensive sequencing test analyzes DNA, RNA, Fusions, and Protein by immunohistochemisty to provide treating physicians and patients with more precise information about the specific cancer pathways in the tumor to allow for more effective decision-making. For more information visit http://www.paradigmdx.com.
SOURCE Paradigm Diagnostics